Efficacy and Safety of Telitacicept Combined With Tofacitinib for Refractory Rheumatoid Arthritis

Recruiting now

Conditions studied: Telitacicept, Treatment Compliance, Rheumatoid Arthritis

In brief

The aim of this study is to observe the clinical efficacy and safety of telitacicept combined with tofacitinib in the treatment of D2TRA patients

Key facts

Study ID

NCT06979271

Run by

Zhejiang Provincial People's Hospital

People needed

20

Starts

2025-06-01

Expected to finish

2027-04-30

Last updated by the study team

2025-05-18

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18-85 years
• Diagnosed with refractory rheumatoid arthritis according to the 2021 EULAR (European Alliance of Associations for Rheumatology) diagnostic criteria
• The traditional disease-improving rheumatic drug treatment is ineffective, and the use of two or more biological/targeted disease-improving anti-rheumatic drugs is ineffective, and telitacicept combined with tofacitinib is required treated patients
• Voluntarily provided written informed consent -

You may not qualify if…

• Exclusion of patients with severe diseases of major organs (e.g., heart, liver, or lungs)
• Patients with malignancies, hematological disorders, or other autoimmune diseases (excluding rheumatoid arthritis)
• History of allergy/hypersensitivity to the study medications (Telitacicept or Tofacitinib)
• Active tuberculosis or active infectious diseases requiring systemic treatment
• Pregnancy, lactation, or refusal to use contraception during the study
• Failure to complete the prescribed Telitacicept + Tofacitinib regimen due to: Non-adherence or Severe adverse reactions
• Other conditions contraindicating participation per investigator judgment -

Where it is running

• Zhejiang Provincial People's Hospital — Hangzhou, Zhejiang, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.